A recombinant heavy chain antibody approach blocks ART2 mediated deletion of an iNKT cell population that upon activation inhibits autoimmune diabetes

Journal of Autoimmunity

Volumn 34, Issue 2, 2010, Pages 145-154

  Scheuplein, Felix ^a   Rissiek, Björn ^b   Driver, John P ^a   Chen, Yi Guang ^a   Koch Nolte, Friedrich ^b   Serreze, David V ^a  

^a JACKSON LABORATORY   (United States)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Autoimmune diabetes; Ectoenzymes; iNKT cells; Single chain antibodies

Indexed keywords

ADP RIBOSYLTRANSFERASE 2.2; ALPHA GALACTOSYLCERAMIDE; CD38 ANTIGEN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN HEAVY CHAIN; RECOMBINANT ANTIBODY; TRANSFERASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ARTICLE; AUTOIMMUNE DISEASE; CATALYSIS; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING;

ADP RIBOSE TRANSFERASES; ANIMALS; ANTIGENS, CD38; DIABETES MELLITUS, TYPE 1; FEMALE; GALACTOSYLCERAMIDES; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOSUPPRESSION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; NATURAL KILLER T-CELLS; PROTEIN ENGINEERING; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES, REGULATORY;

EID: 75349113325     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2009.08.012     Document Type: Article

References (38)

1. Okamoto S., Azhipa O., Yu Y., Russo E., and Dennert G. Expression of ADP-ribosyltransferase on normal T lymphocytes and effects of nicotinamide adenine dinucleotide on their function. J Immunol 160 (1998) 4190-4198
2. Ohlrogge W., Haag F., Lohler J., Seman M., Littman D.R., Killeen N., et al. Generation and characterization of ecto-ADP-ribosyltransferase ART2.1/ART2.2-deficient mice. Mol Cell Biol 22 (2002) 7535-7542
3. Seman M., Adriouch S., Scheuplein F., Krebs C., Freese D., Glowacki G., et al. NAD-induced T cell death: aDP-ribosylation of cell surface proteins by ART2 activates the cytolytic P2X7 purinoceptor. Immunity 19 (2003) 571-582
4. Krebs C., Adriouch S., Braasch F., Koestner W., Leiter E.H., Seman M., et al. CD38 controls ADP-ribosyltransferase-2-catalyzed ADP-ribosylation of T cell surface proteins. J Immunol 174 (2005) 3298-3305
5. Chen J., Chen Y.G., Reifsnyder P.C., Schott W.H., Lee C.H., Osborne M., et al. Targeted disruption of CD38 accelerates autoimmune diabetes in NOD/Lt mice by enhancing autoimmunity in an ADP-ribosyltransferase 2-dependent fashion. J Immunol 176 (2006) 4590-4599
6. Glowacki G., Braren R., Firner K., Nissen M., Kuhl M., Reche P., et al. The family of toxin-related ecto-ADP-ribosyltransferases in humans and the mouse. Protein Sci 11 (2002) 1657-1670
7. Banasik M., Komura H., Shimoyama M., and Ueda K. Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferase. J Biol Chem 267 (1992) 1569-1575
8. Koch-Nolte F., Reyelt J., Schossow B., Schwarz N., Scheuplein F., Rothenburg S., et al. Single domain antibodies from llama effectively and specifically block T cell ecto-ADP-ribosyltransferase ART2.2 in vivo. FASEB J 21 (2007) 3490-3498
9. Wesolowski J., Alzogaray V., Reyelt J., Unger M., Juarez K., Urrutia M., et al. Single domain antibodies: promising experimental and therapeutic tools in infection and immunity. Med Microbiol Immunol (2009)
10. Ghetie V., Popov S., Borvak J., Radu C., Matesoi D., Medesan C., et al. Increasing the serum persistence of an IgG fragment by random mutagenesis. Nat Biotechnol 15 (1997) 637-640
11. Baschal E.E., and Eisenbarth G.S. Extreme genetic risk for type 1A diabetes in the post-genome era. J Autoimmun 31 (2008) 1-6
12. Harrison L.C., Honeyman M.C., Morahan G., Wentworth J.M., Elkassaby S., Colman P.G., et al. Type 1 diabetes: lessons for other autoimmune diseases?. J Autoimmun 31 (2008) 306-310
13. Hammond K.J., Pellicci D.G., Poulton L.D., Naidenko O.V., Scalzo A.A., Baxter A.G., et al. CD1d-restricted NKT cells: an interstrain comparison. J Immunol 167 (2001) 1164-1173
14. Kronenberg M. Toward an understanding of NKT cell biology: progress and paradoxes. Annu Rev Immunol 23 (2005) 877-900
15. Chen Y.G., Choisy-Rossi C.M., Holl T.M., Chapman H.D., Besra G.S., Porcelli S.A., et al. Activated NKT cells inhibit autoimmune diabetes through tolerogenic recruitment of dendritic cells to pancreatic lymph nodes. J Immunol 174 (2005) 1196-1204
16. Hammond K.J., Poulton L.D., Palmisano L.J., Silveira P.A., Godfrey D.I., and Baxter A.G. alpha/beta-T cell receptor (TCR)+CD4-CD8- (NKT) thymocytes prevent insulin-dependent diabetes mellitus in nonobese diabetic (NOD)/Lt mice by the influence of interleukin (IL)-4 and/or IL-10. J Exp Med 187 (1998) 1047-1056
17. Hong S., Wilson M.T., Serizawa I., Wu L., Singh N., Naidenko O.V., et al. The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat Med 7 (2001) 1052-1056
18. Naumov Y.N., Bahjat K.S., Gausling R., Abraham R., Exley M.A., Koezuka Y., et al. Activation of CD1d-restricted T cells protects NOD mice from developing diabetes by regulating dendritic cell subsets. Proc Natl Acad Sci U S A 98 (2001) 13838-13843
19. Sharif S., Arreaza G.A., Zucker P., Mi Q.S., Sondhi J., Naidenko O.V., et al. Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes. Nat Med 7 (2001) 1057-1062
20. DiLorenzo T.P., Lieberman S.M., Takaki T., Honda S., Chapman H.D., Santamaria P., et al. During the early prediabetic period in NOD mice, the pathogenic CD8(+) T-cell population comprises multiple antigenic specificities. Clin Immunol (Orlando, Fla.) 105 (2002) 332-341
21. Koch-Nolte F., Duffy T., Nissen M., Kahl S., Killeen N., Ablamunits V., et al. A new monoclonal antibody detects a developmentally regulated mouse ecto-ADP-ribosyltransferase on T cells: subset distribution, inbred strain variation, and modulation upon T cell activation. J Immunol 163 (1999) 6014-6022
22. Krebs C., Koestner W., Nissen M., Welge V., Parusel I., Malavasi F., et al. Flow cytometric and immunoblot assays for cell surface ADP-ribosylation using a monoclonal antibody specific for ethenoadenosine. Anal Biochem 314 (2003) 108-115
23. Serreze D.V., Johnson E.A., Chapman H.D., Graser R.T., Marron M.P., DiLorenzo T.P., et al. Autoreactive diabetogenic T-cells in NOD mice can efficiently expand from a greatly reduced precursor pool. Diabetes 50 (2001) 1992-2000
24. Haag F., Freese D., Scheuplein F., Ohlrogge W., Adriouch S., Seman M., et al. T cells of different developmental stages differ in sensitivity to apoptosis induced by extracellular NAD. Dev Immunol 9 (2002) 197-202
25. Chen Y.G., Chen J., Osborne M.A., Chapman H.D., Besra G.S., Porcelli S.A., et al. CD38 is required for the peripheral survival of immunotolerogenic CD4+ invariant NK T cells in nonobese diabetic mice. J Immunol 177 (2006) 2939-2947
26. Hong S., Brass A., Seman M., Haag F., Koch-Nolte F., and Dubyak G.R. Lipopolysaccharide, IFN-gamma, and IFN-beta induce expression of the thiol-sensitive ART2.1 ecto-ADP-ribosyltransferase in murine macrophages. J Immunol 179 (2007) 6215-6227
27. Scheuplein F., Schwarz N., Adriouch S., Krebs C., Bannas P., Rissiek B., et al. NAD+ and ATP released from injured cells induce P2X7-dependent shedding of CD62L and externalization of phosphatidylserine by murine T cells. J Immunol 182 (2009) 2898-2908
28. Ly D., Mi Q.S., Hussain S., and Delovitch T.L. Protection from type 1 diabetes by invariant NK T cells requires the activity of CD4+CD25+ regulatory T cells. J Immunol 177 (2006) 3695-3704
29. Wilson S.B., Kent S.C., Patton K.T., Orban T., Jackson R.A., Exley M., et al. Extreme Th1 bias of invariant Valpha24JalphaQ T cells in type 1 diabetes. Nature 391 (1998) 177-181
30. Lee P.T., Putnam A., Benlagha K., Teyton L., Gottlieb P.A., and Bendelac A. Testing the NKT cell hypothesis of human IDDM pathogenesis. J Clin Invest 110 (2002) 793-800
31. Barrett J.C., Clayton D.G., Concannon P., Akolkar B., Cooper J.D., Erlich H.A., et al. Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat Genet (2009)
32. Wilson S.B., and Delovitch T.L. Janus-like role of regulatory iNKT cells in autoimmune disease and tumour immunity. Nat Rev Immunol 3 (2003) 211-222
33. Nakamura T., Sonoda K.H., Faunce D.E., Gumperz J., Yamamura T., Miyake S., et al. CD4+ NKT cells, but not conventional CD4+ T cells, are required to generate efferent CD8+ T regulatory cells following antigen inoculation in an immune-privileged site. J Immunol 171 (2003) 1266-1271
34. Roelofs-Haarhuis K., Wu X., and Gleichmann E. Oral tolerance to nickel requires CD4+ invariant NKT cells for the infectious spread of tolerance and the induction of specific regulatory T cells. J Immunol 173 (2004) 1043-1050
35. Terabe M., Matsui S., Noben-Trauth N., Chen H., Watson C., Donaldson D.D., et al. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol 1 (2000) 515-520
36. De Genst E., Silence K., Decanniere K., Conrath K., Loris R., Kinne J., et al. Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies. Proc Natl Acad Sci U S A 103 (2006) 4586-4591
37. Lauwereys M., Arbabi Ghahroudi M., Desmyter A., Kinne J., Holzer W., De Genst E., et al. Potent enzyme inhibitors derived from dromedary heavy-chain antibodies. EMBO J 17 (1998) 3512-3520
38. Hmila I., Abdallah R.B., Saerens D., Benlasfar Z., Conrath K., Ayeb M.E., et al. VHH, bivalent domains and chimeric heavy chain-only antibodies with high neutralizing efficacy for scorpion toxin AahI'. Mol Immunol 45 (2008) 3847-3856